GET DAILY SIGNALSIQVIA (IQV) Delivers +8% Revenue Growth in Q3 and Raises Full-Year Guidance
Key Takeaways
- Revenue reached $4,428 million, up 8.0% year-over-year and slightly above the roughly $4.37 billion consensus estimate.
- Adjusted diluted EPS of $3.34 rose 11.3% year-over-year, topping the consensus estimate of about $3.28.
- Research & Development Solutions net new bookings hit $3.2 billion, up 15% and the strongest clinical quarterly bookings since 2022, with a book-to-bill ratio of 1.2x.
- Management raised full-year 2026 guidance across revenue, Adjusted EBITDA, and Adjusted Diluted EPS.
- Free cash flow of $667 million equaled 120% of Adjusted Net Income, highlighting strong cash conversion.
Why These Results Matter for Investors
IQVIA Holdings is a leading global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences industry. Its quarterly results serve as a useful barometer of pharmaceutical R&D spending and outsourcing demand. The company had beaten consensus estimates in each of the prior four quarters, backed by improving biotech funding and stronger RFP activity. This third-quarter update therefore provides insight not only into IQVIA's own path but also into the broader health of the life sciences outsourcing market.
Breaking Down the Q3 Numbers
For the third quarter ended September 30, 2026, IQV reported revenue of $4,428 million, an increase of 8.0% on a reported basis and 8.6% at constant currency, compared with $4,100 million a year earlier. The result exceeded the consensus estimate of approximately $4.37 billion. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
GAAP net income was $350 million, with GAAP diluted EPS of $2.10. On an adjusted basis, net income was $557 million and Adjusted Diluted EPS was $3.34, up 11.3% year-over-year and above the consensus estimate of roughly $3.28. Adjusted EBITDA reached $1,032 million, up 8.7%.
Both operating segments contributed to growth. Commercial Solutions revenue rose 6.9% to $1,789 million, while Research & Development Solutions revenue grew 8.7% to $2,639 million. R&D Solutions net new bookings of $3.2 billion climbed 15% year-over-year, representing a 1.2x book-to-bill ratio. The company also completed a review of inactive trials that reduced contracted backlog by approximately $2.1 billion, leaving R&D Solutions contracted backlog at $32.6 billion. Management expects about $9.4 billion of that backlog to convert to revenue over the next twelve months, up 10% year-over-year.
How the Market Reacted
Despite results that beat consensus estimates on revenue and adjusted EPS, IQV shares traded modestly lower following the announcement. The stock had already climbed to the upper end of its 52-week range in the weeks before the report, and several analysts had raised price targets ahead of earnings. Management's commentary was upbeat, with Chief Executive Officer Ari Bousbib citing favorable demand indicators across biotech funding, RFP flow, clinical trial starts, and FDA approvals. Investor attention quickly moved to the raised full-year guidance and the strength of forward bookings.
What to Watch Going Forward
IQV raised its full-year 2026 guidance, now expecting revenue between $17,350 million and $17,500 million, Adjusted EBITDA between $4,025 million and $4,055 million, and Adjusted Diluted EPS between $12.90 and $13.00. The updated revenue outlook anticipates roughly 250 basis points of contribution from acquisitions expected to close by year-end, along with a modest foreign-exchange tailwind.
Bookings and the book-to-bill ratio remain the clearest leading indicators of future revenue, and sustained growth above 1.0x would reinforce the demand recovery. The company's AI investments are another area of focus, with management reporting more than 400 AI agents deployed to date. Margin trends and the pace of pass-through revenue will also matter for Adjusted EBITDA expansion. Finally, IQVIA plans to host an Investor Day on December 1, 2026, where it is expected to provide a framework for 2027.
Tools That Help Me Stay on Top of Earnings Season
When reviewing results like these, I often turn to Tickeron’s AI Screener to quickly compare IQV against peers on key metrics and spot any emerging patterns in the sector. It helps me cut through the noise and focus on what actually drives the numbers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for IQV turns positive, indicating new upward trend
IQV saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned positive. In 52 of the 76 cases, the stock moved higher in the following days. The odds of a move higher are at 68%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for IQV just turned positive on October 21, 2026. Looking at past instances where IQV's MACD turned positive, the stock continued to rise in 24 of 42 cases over the following month. The odds of a continued upward trend are 57%.
Following a +0.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where IQV advanced for three days, in 187 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 120 of 222 cases where IQV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IQV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
IQV broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. IQV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 43 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.298) is normal, around the industry mean (65.624). P/E Ratio (33.695) is within average values for comparable stocks, (2.414). Projected Growth (PEG Ratio) (0.985) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.693) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 84 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IQV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock better than average.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical development services and commercial outsourcing services
Industry MedicalSpecialties
Advertisement